PepGen (PEPG) Current Assets (2021 - 2026)
PepGen (PEPG) posted Current Assets of $134.3 million for Q1 2026, down 11.06% sequentially from $151.0 million in Q4 2025, and up 32.88% YoY from $101.0 million in Q1 2025.
Analysis
PepGen (PEPG) Current Assets (2021 - 2026) Analysis & Trends
PepGen has reported Current Assets for 6 years, with the latest figure at $134.3 million in Q1 2026.
- Quarterly Current Assets rose 32.88% year-over-year to $134.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $134.3 million (up 32.88% YoY) and the FY2025 annual result came in at $151.0 million, up 21.98% from the prior year.
- Current Assets slipped to $134.3 million in Q1 2026 per PEPG's latest filing, from $151.0 million in the prior quarter.
- Over five years, Current Assets peaked at $226.5 million in Q2 2022 and troughed at $77.5 million in Q2 2025.
- A 5-year average of $149.7 million and a median of $150.4 million in 2023 frame the typical range for Current Assets.
- The sharpest annual moves came in 2023 and 2025: Current Assets soared 34.06% in 2023, then slumped 52.98% in 2025.
- Over 5 years, Current Assets stood at $186.1 million in 2022, then tumbled by 39.45% to $112.7 million in 2023, then grew by 9.84% to $123.8 million in 2024, then climbed by 21.98% to $151.0 million in 2025, then decreased by 11.06% to $134.3 million in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $134.3 million, $151.0 million, and $166.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.82 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.03 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 7.22 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 4.62 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 1.76 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.63 Bn |
| 10 | PepGen | 217.99 Mn | 217.99 Mn | - | 120.33 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 120.33 Mn |
| Mar 31, 2026 | 134.27 Mn |
| Dec 31, 2025 | 150.96 Mn |
| Sep 30, 2025 | 166.21 Mn |
| Jun 30, 2025 | 77.49 Mn |
| Mar 31, 2025 | 101.05 Mn |
| Dec 31, 2024 | 123.76 Mn |
| Sep 30, 2024 | 142.37 Mn |
| Jun 30, 2024 | 164.78 Mn |
| Mar 31, 2024 | 177.62 Mn |
| Dec 31, 2023 | 112.68 Mn |
| Sep 30, 2023 | 133.09 Mn |
| Jun 30, 2023 | 150.38 Mn |
| Mar 31, 2023 | 168.47 Mn |
| Dec 31, 2022 | 186.08 Mn |
| Sep 30, 2022 | 204.25 Mn |
| Jun 30, 2022 | 226.48 Mn |
| Mar 31, 2022 | 125.67 Mn |
| Dec 31, 2021 | 139.99 Mn |